Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Patients Admitted to Sina Hospital in Hamadan, Iran: A 16-year study

Background and Objective: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe and potentially life-threatening reactions. In spite of the low prevalence of these conditions, they are of utmost significance due to their catastrophic complications and mortality. The SJS and TEN are mostly caused by a reaction to a drug; however, in some cases, they result from infections. The aim of this study was to investigate the epidemiologic, etiologic, and clinical characteristics of the patients admitted to Sina Hospital in Hamadan, Iran, due to SJS and TEN during a 16-year period. Materials and Methods: This cross-sectional descriptive study was conducted on the patients with SJS and TEN admitted to Sina Hospital during the last 16 years (i.e., 2002-2018). The data analyzed in the present study included age, gender, causative drug, length of hospital stay, received treatment, and complications. Results: A total of 47 patients, consisting of 21 males and 26 females, were investigated in this study. Out of the 47 patients, 34, 9, and 4 cases were diagnosed with SJS, TEN, and SJS/TEN overlap, respectively. Regarding the etiology of these conditions, 45 cases (95.7%) were drug-related, while the remaining 2 cases were caused by reasons other than drugs. The most common causative drugs were antimicrobials (36.1%), followed by antiepileptics (27.6%) and nonsteroidal anti-inflammatory drug (17 %). Furthermore, there one case caused by reaction to allopurinol, and another case resulted from reactions to rabies vaccine. The remaining cases were either non-drug related or multi-drug related. The most common complications were infections (21.2%), followed by ocular problems (19.1%) and gastrointestinal bleeding (2.1%). Conclusion: As the findings indicated, antimicrobials were the most common causative drugs of SJS and TEN. The physicians should be aware of the clinical manifestations of SJS and TEN with regard to the severe complications of these conditions, including ocular damages, and their risk of mortality. Moreover, it is required to enhance public awareness regarding the avoidance of self-medication with antimicrobial drugs.

[1]  H. Raeisi Shahraki,et al.  An Epidemiological Study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis during 2010-2015 at Shahid Faghihi Hospital, Shiraz, Iran , 2018, Iranian journal of medical sciences.

[2]  Xusheng Du,et al.  First case of Stevens–Johnson syndrome after rabies vaccination , 2018, British journal of clinical pharmacology.

[3]  T. Harr,et al.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis , 2018, Clinical Reviews in Allergy & Immunology.

[4]  L. Göttems,et al.  Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiological and clinical outcomes analysis in public hospitals* , 2017, Anais brasileiros de dermatologia.

[5]  Li Wang,et al.  Retrospective Analysis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in 88 Chinese Patients , 2017, Chinese medical journal.

[6]  Philip R. Cohen,et al.  Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures , 2017, Advances in Therapy.

[7]  A. Felipe,et al.  Toxic Epidermal Necrolysis Successfully Treated With Infliximab , 2017 .

[8]  J. Chodosh,et al.  Complications of Stevens-Johnson syndrome beyond the eye and skin. , 2016, Burns : journal of the International Society for Burn Injuries.

[9]  A. Papp,et al.  Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. , 2014, Journal of the American Academy of Dermatology.

[10]  F. Mokhtari,et al.  Adverse cutaneous drug reactions: Eight year assessment in hospitalized patients , 2014, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[11]  V. Scott-Lang,et al.  Toxic Epidermal Necrolysis in a Child Successfully Treated with Infliximab , 2014, Pediatric dermatology.

[12]  B. M. Taylor,et al.  Toxic Epidermal Necrolysis from suspected Mycoplasma pneumoniae infection. , 2013, Military medicine.

[13]  R. Verma,et al.  Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid. , 2013, Indian journal of dermatology, venereology and leprology.

[14]  W. Tassaneeyakul,et al.  Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. , 2013, JAMA dermatology.

[15]  M. Barvaliya,et al.  A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population. , 2013, Indian journal of dermatology, venereology and leprology.

[16]  N. Lai,et al.  An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. , 2012, Indian journal of dermatology, venereology and leprology.

[17]  J. Roujeau,et al.  Toxic epidermal necrolysis, DRESS, AGEP: Do overlap cases exist? , 2012, Orphanet Journal of Rare Diseases.

[18]  N. Chaiyakunapruk,et al.  Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis , 2011, BMC Medical Genetics.

[19]  Limei Zhao,et al.  Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients , 2011, European Journal of Clinical Pharmacology.

[20]  陳建勳,et al.  Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan , 2011 .

[21]  M. Iijima,et al.  Erythema multiforme, Stevens–Johnson syndrome and toxic epidermal necrolysis: Frozen‐section diagnosis , 2010, The Journal of dermatology.

[22]  A. Kołtan,et al.  Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis. , 2008, Acta dermato-venereologica.

[23]  C. Foster,et al.  Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. , 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[24]  V. Sehgal,et al.  Toxic epidermal necrolysis (TEN) Lyell's syndrome , 2005, The Journal of dermatological treatment.

[25]  C. Demirkesen,et al.  Toxic Epidermal Necrolysis after Cranial Radiotherapy and Phenytoin Treatment , 2004, Oncology Research and Treatment.

[26]  F. Tas,et al.  Stevens‐Johnson Syndrome in a Patient Receiving Anticonvulsant Therapy During Cranial Irradiation , 2001, American journal of clinical oncology.

[27]  A. Munster,et al.  Toxic Epidermal Necrolysis Syndrome: Mortality Rate Reduced with Early Referral to Regional Burn Center , 1998, Plastic and reconstructive surgery.

[28]  J. Hunt,et al.  Toxic epidermal necrolysis. , 1997, The Journal of burn care & rehabilitation.

[29]  M. Mockenhaupt,et al.  Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. , 1996, Journal of clinical epidemiology.

[30]  R. Patterson,et al.  The outcome of Stevens-Johnson syndrome treated with corticosteroids. , 1995, Allergy proceedings : the official journal of regional and state allergy societies.

[31]  R. Stern,et al.  Severe adverse cutaneous reactions to drugs. , 1994, The New England journal of medicine.

[32]  G. Shires,et al.  Improved Burn Center Survival of Patients with Toxic Epidermal Necrolysis Managed without Corticosteroids , 1986, Annals of surgery.

[33]  Y. Yamaguchi,et al.  Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome. , 2016, Allergology international : official journal of the Japanese Society of Allergology.

[34]  L. Naldi,et al.  Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. , 2008, Journal of the American Academy of Dermatology.

[35]  B. Thiers.  HLA-B*5801 Allele as a Genetic Marker for Severe Cutaneous Adverse Reactions Caused by Allopurinol , 2006 .

[36]  J. Roujeau,et al.  Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. , 2002, Dermatology online journal.

[37]  H. Schultz,et al.  Stevens-Johnson syndrome in patients on phenytoin and cranial radiotherapy. , 1999, Acta oncologica.

[38]  J. Roujeau,et al.  Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection. , 1995, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.

[39]  H. Baart de la Faille,et al.  Management of nonstaphylococcal toxic epidermal necrolysis: follow-up study of 16 case histories. , 1990, Dermatologica.